# Cypherpunk Technologies Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Cypherpunk Technologies Inc). ## Overview Cypherpunk Technologies Inc. is a U.S.-based company that has shifted from its historical biopharmaceutical development work toward a digital asset treasury strategy centered on Zcash (ZEC). The company still retains its legacy research and development activities through its wholly owned subsidiary, Leap Therapeutics, Inc., including a clinical-stage oncology program and a preclinical cachexia program. In parallel, it is building a balance-sheet strategy around acquiring and holding ZEC and participating in the Zcash ecosystem. This makes the company unusual in that it combines a legacy biotech development platform with a crypto-treasury model focused on privacy-oriented digital assets. ## Products & services • Clinical-stage sirexatamab (DKN-01) oncology program • Preclinical FL-501 cachexia antibody program • Zcash (ZEC) treasury accumulation strategy • Digital asset custody and trading via Gemini • Participation in the Zcash community/ecosystem - **Biopharmaceutical R&D** (0%) — Includes the company’s oncology and cachexia antibody programs, clinical trials, and related development work. - **Digital Asset Treasury** (100%) — Includes acquisition and holding of Zcash (ZEC) as a balance-sheet reserve asset and related treasury management. - **Digital Asset Operations** (0%) — Includes trading execution, custody, and storage infrastructure used to manage ZEC holdings through third parties. - Clinical-stage sirexatamab (DKN-01) antibody therapy for cancer - Preclinical FL-501 antibody program for cachexia-related indications - Zcash (ZEC) digital asset treasury accumulation - Custodied digital asset execution and storage through Gemini - Active participation in the Zcash community and protocol ecosystem ## Customers The company does not currently sell approved pharmaceutical products, so it has no traditional commercial customer base in its legacy biotech business. Its biopharmaceutical work is aimed at cancer patients and, indirectly, the physicians, clinical investigators, and trial sites that support development programs. In its new digital asset strategy, the relevant counterparties are not end customers in the usual sense but rather exchanges, custodians, and market participants that facilitate ZEC acquisition and storage. Investors in the public company are also an important audience because the treasury strategy is intended to create exposure to ZEC through listed equity ownership. - **Clinical trial participants and oncology care ecosystem** (primary) — Patients, physicians, and trial sites involved in evaluating sirexatamab and related cancer therapies. - **Digital asset service providers** (primary) — Custodians and trading venues such as Gemini that execute purchases and hold ZEC on the company’s behalf. - **Public equity investors** (primary) — Investors buying the listed shares for exposure to the company’s ZEC holdings and optionality on the legacy biotech pipeline. - **Zcash ecosystem participants** (secondary) — Developers, community members, and protocol stakeholders that the company intends to engage with as an active ZEC holder. - Cancer patients are the ultimate end beneficiaries of the oncology pipeline - Oncologists and clinical investigators support enrollment and trial execution - Hospitals and trial sites participate in clinical development programs - Gemini and other service providers support ZEC trading and custody - Public-market investors seek equity exposure to the ZEC treasury strategy ## Geography The company is headquartered in the United States and reports under U.S. GAAP, so its operating, financing, and regulatory exposure is primarily U.S.-based. Its digital asset treasury activities depend on U.S. market infrastructure, including Gemini as custodian and exchange execution venue. The company also faces U.S. federal and state regulatory scrutiny around digital assets, which can affect how it operates and how investors value the stock. Its legacy biotech activities are conducted through a U.S.-based corporate structure, although clinical development may involve external research sites and service providers. - United States is the core operating and regulatory base - Digital asset custody and execution are tied to U.S.-based Gemini infrastructure - U.S. federal and state digital asset rules are a key operating constraint - Clinical development and R&D are managed from the U.S. corporate structure - No country-level revenue disclosure was provided in the excerpts ## Strategy The company’s near-term strategy is to deploy capital into Zcash and build a public-market treasury vehicle around a privacy-focused digital asset. Management has explicitly stated that it intends to acquire and hold ZEC as the primary digital asset and to participate actively in the Zcash community. At the same time, it is preserving its legacy biopharmaceutical R&D through Leap Therapeutics, which keeps a potential clinical-development option alive. The strategy depends on building the operational, compliance, and custody infrastructure needed to manage digital assets while navigating volatile markets and evolving regulation. - **Build and scale the ZEC treasury** (short-term) — The company is repositioning around Zcash holdings, so treasury execution is central to its new identity and valuation. - **Strengthen digital asset operations and controls** (short-term) — Custody, trading execution, security, and compliance are critical to protecting assets and executing the strategy safely. - **Preserve biotech optionality** (medium-term) — The legacy oncology program may still create value and provides a non-crypto strategic asset base. - Accumulate ZEC as the primary treasury asset - Use public equity capital to fund digital asset purchases - Participate in the Zcash community and ecosystem - Maintain legacy oncology R&D through Leap Therapeutics - Build custody, security, and compliance infrastructure for digital assets - Preserve optionality from the biotech pipeline while treasury strategy scales ## Risks The company faces substantial execution risk because it is shifting into a digital asset treasury model that requires new operational, technical, and compliance capabilities. ZEC is highly volatile, so changes in token price can quickly affect reported results and investor sentiment. The company is also dependent on Gemini for custody and trading execution, which creates counterparty and operational concentration risk. In addition, U.S. federal and state digital asset regulation remains unsettled, while the legacy biotech business still carries clinical development, funding, and going-concern risk because it has no approved product or product revenue. - **Failure to execute the digital asset treasury strategy** [high] — The company is entering a new operating model that requires specialized skills, controls, and infrastructure it may not build in time. - **ZEC price volatility** [high] — The company plans to hold a significant portion of capital in ZEC, so market swings directly affect asset value and earnings. - **Custody and counterparty concentration at Gemini** [high] — ZEC holdings are concentrated with a single custodian and the company has limited control over storage and execution systems. - **Regulatory uncertainty for digital assets** [high] — Evolving SEC, Nasdaq, federal, and state rules could restrict or complicate the treasury strategy. - **Clinical development and financing risk in biotech** [medium] — The legacy R&D business has no approved products and depends on continued capital access and trial success. - Digital asset strategy may fail to scale or be implemented effectively - ZEC price volatility can materially affect reported results and stock price - Single-custodian concentration creates counterparty and operational risk - Regulatory uncertainty could force changes to treasury operations - Cybersecurity and network integrity risks could impair Zcash value - Legacy biotech pipeline remains clinical-stage with no product revenue - Going-concern and financing risk remain relevant due to ongoing losses ## Accounting The most important accounting issue is fair value measurement of ZEC, because the company adopted crypto-asset accounting that requires holdings to be marked to quoted market prices each reporting period. That means unrealized gains and losses can create large swings in net income without any cash movement, reducing comparability across quarters and between periods before adoption. The company also has significant judgment around accrued research and development expenses, because clinical trial and manufacturing costs are often estimated before invoices are finalized. Stock-based compensation and the research and development incentive receivable are additional estimate-heavy areas that can materially affect reported expenses and balance sheet values. - **Fair value accounting for ZEC holdings** — Net income, balance sheet, and quarter-to-quarter comparability - **Accrued research and development expenses** — Operating expenses and liabilities - **Research and development incentive receivable** — Assets and R&D expense presentation - **Stock-based compensation** — Operating expense and shareholder dilution - ZEC is measured at fair value, so price changes flow through earnings - Unrealized crypto gains and losses can create large non-cash volatility - Clinical trial accruals require estimates for outsourced R&D and manufacturing - Research and development incentive receivable depends on judgment and timing - Stock-based compensation affects operating expense and equity dilution analysis - Results after crypto adoption are not comparable with pre-adoption periods --- *Last updated: 2026-09-24T10:46:59.152233+00:00*